How mRNA Technology Is Expanding Beyond COVID to Cancer and Rare Diseases

mRNA technology proven by COVID vaccines is expanding rapidly. BioNTech and Moderna have 50+ clinical trials for cancer vaccines, targeting melanoma, lung cancer, and pancreatic cancer. Rare disease applications using mRNA to produce missing proteins. The speed advantage (design to manufacturing in weeks) makes mRNA ideal for pandemic preparedness. Challenges: personalized cancer vaccines require individual tumor sequencing, increasing cost and complexity.